Subject(s)
Factor XII Deficiency/complications , Heart Transplantation/methods , Heart Valve Diseases/complications , Mitral Valve/surgery , 4-Hydroxycoumarins/therapeutic use , Adult , Anticoagulants/therapeutic use , Blood Transfusion/methods , Cardiopulmonary Bypass/methods , Heparin/therapeutic use , Heparin Antagonists/therapeutic use , Humans , Indenes/therapeutic use , Male , Monitoring, Intraoperative/methods , Plasma/physiology , Protamines/therapeutic use , Vitamin K/antagonists & inhibitors , Vitamin K/therapeutic use , Whole Blood Coagulation Time/methodsABSTRACT
Brugada syndrome is characterized by a distinctive electrocardiographic pattern (right bundle branch block and ST segment elevation in precordial leads) and a high risk of cardiac arrest for malignant dysrhythmia. The genetic basis is a molecular defect of the cardiac sodium channel and the pattern of inheritance is autosomal dominant. Many factors during general anesthesia (medications, bradycardia, temperature changes) could precipitate malignant dysrhythmia in these patients. Because criteria to identify the surgical patient at high risk for developing malignant dysrhythmia are lacking, we can only speculate about the available studies on nonsurgical patients. We describe four patients during general anesthesia and propose intraoperative and postoperative monitoring (the first 36 h).
